The Challenges Of Valuing Litigation-Driven Equities
Many eyes are on the Delaware Court of Chancery to see whether it will compel Fresenius SE to close on a $4.5 billion acquisition of generic drugmaker Akorn Inc. Fresenius terminated...To view the full article, register now.
Already a subscriber? Click here to view full article